|The following article features coverage from the American Society of Clinical Oncology (ASCO) 2018 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Two-year follow-up data from a previous interim analysis dives deeper into the benefit of web-mediated follow-up based on patient-reported outcomes compared with routine surveillance in patients with lung cancer and was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, on Friday, June 1.1
Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer who were given web-based monitoring to detect recurrence after initial treatment compared with scheduled imaging. The researchers theorized that this benefit in overall survival was linked to earlier detection of symptoms and relapses.
Between June 2014 and January 2016, 121 patients were enrolled in the intent-to-test survival analysis. Upon completion of the interim analysis, 10 of the 34 living patients in the control arm were eligible to cross over to the experimental arm of the study. After 2 years of follow-up and 70 deaths observed, the median overall survival was 23 months in the experimental arm and 14.8 months in the control arm without adjustment for crossover (HR 0.62, 95% CI 0.39-0.995, P = .048). Censoring crossover resulted in a hazard ratio of 0.53 (95% CI 0.33-0.85, P = .009).
After the longer follow-up and despite the crossover of eligible patients, the overall survival findings remained longer for patients with were given web-mediated follow-up based on patient-reported outcomes compared with routine follow-up via CT scan.
“This is the first study to show the benefits of PROs during surveillance in cancer patients,” the authors concluded.
Read more of Cancer Therapy Advisor‘s coverage of the American Society of Clinical Oncology (ASCO) 2018 meeting by visiting the conference page.
- Denis F, Basch EM, Lehtrosne C, et al. Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (PRO) vs. routine surveillance in lung cancer patients: Final results. J Clin Oncol. 2018: 36, (suppl; abstr 6500). Presented at 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, IL.